BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Innate Immunotherapeutics Completes $10 Million IPO


12/18/2013 9:36:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SYDNEY--(BUSINESS WIRE)--Innate Immunotherapeutics is pleased to announce it has successfully raised A$10 million through its Initial Public Offer (IPO) and will immediately commence planning its clinical trial for MIS416, the Company’s lead drug for the treatment of Secondary Progressive Multiple Sclerosis (SPMS).

The IPO has received strong support from existing international shareholders and new Australian institutional investors, with Patersons Securities Limited and Morgans Corporate Limited joint lead managers. In addition to the new funding, prior debt holders participated in the IPO by conversion of their debt and as a result the Company has no remaining loan obligations.

“The IPO has provided the Company with the funds to finance a placebo controlled Phase 2B efficacy study of MIS416 in Australian patients with SPMS,” said Simon Wilkinson, CEO of Innate Immunotherapeutics. “These patients do not have access to effective long-term treatments and so with the close of the IPO we can now move rapidly to get the efficacy trial underway,” he added.

Innate Immunotherapeutics has previously completed Phase 1B/2A trials in New Zealand during which the drug raised no evident safety concerns and, in most patients treated for three months, showed clear signs of positive effect. These trials were funded in part by the US National MS Society (NMSS) and the New Zealand Government. The Company has also made MIS416 available to a small group of former trial participants and other patients with SPMS in New Zealand on compassionate grounds. Fourteen of the 17 patients treated for up to five years under this exemption in the New Zealand drug laws have reported significant improvements in a range of their disease related disabilities.

On successful completion of the Phase 2B trial, expected in late 2015, the Company’s strategy is to maximise the value of the technology through a major partnering transaction. Pharmaceutical companies participating in the US$11bn early stage MS market are understood to be actively seeking drugs to treat SPMS, and the Company has engaged early and positively with a number of these companies.

About Multiple Sclerosis (MS)

Multiple Sclerosis (MS) is a chronic disease of the central nervous system, where the body’s immune system attacks the myelin sheath surrounding the nerve fibres. The damaged myelin disrupts the communication mechanism of parts of the central nervous system. This results in a wide range of symptoms, which may include loss of balance and muscle coordination, difficulty walking, slurred speech, tremors, stiffness, cognitive impairment, depression, fatigue and bladder problems. There are two main forms of MS, an early ‘relapsing-remitting’ stage of disease and, a later, more disabling ‘secondary-progressive’ stage of disease. Worldwide, 30% of all multiple sclerosis (MS) sufferers have SPMS and there are currently no approved disease modifying drugs for the safe and effective, ongoing treatment of this highly disabling form of the disease.

About MIS416

The microparticle, MIS416, is biologically derived and can target both the regulatory functions and the defensive (pathogenic) functions of the innate immune system. The innate immune system is the body’s first line of defence against external disease causing agents (pathogens) such as bacteria and viruses, and internally caused diseases such as cancer. Apart from MS, disorders of the immune system can also cause or contribute to autoimmune diseases such type 1 diabetes, inflammatory diseases such as rheumatoid arthritis, and inflammatory bowel disease.

For Further Information

Company:
http://www.innateimmuno.com/

Contacts

Media:
Buchan Consulting
Kellie Hanrick, 03 9866 4722
khanrick@buchanwe.com.au

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES